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I. INTRODUCTION
According to the American Cancer Society, "[c]ancer is the second leading
cause of death in the United States."' Over 500,000 people died from cancer in
* J.D., with great distinction, University of the Pacific, McGeorge School of Law, 2005; B.S.,
Mechanical Engineering, University of Washington, 2001.
The author would like to note that he drafted this comment primarily during the 2003-04 academic year.
Subsequently, the Supreme Court decided a case involving the experimental use defense to patent infringement.
See Merck KGaA v. Integra Lifesciences L Ltd., 125 S. Ct. 2372 (2005). However, Merck concerns an
interpretation of the statutory experimental use exemption under 35 U.S.C. § 271(e)(1). See id. at 2383-84
(holding that uses of patented inventions in preclinical research, the results of which are not ultimately
submitted to the Food and Drug Administration, are exempted from infringement under section 271(e)(1)).
Merck did not address the common law experimental use defense. Accordingly, the principal case discussed
herein, Madey v. Duke University, 307 F.3d 1351 (Fed. Cir. 2002), remains good law and is the most important
decision to date involving the common law experimental use defense. In addition, in the interim between
drafting this comment and publishing it, several articles have been published which discuss nanotechnology and
patent law. See, e.g., Mark A. Lemley, Patenting Nanotechnology, 58 STAN. L. REV. 601 (2005).
1. American Cancer Society, What is Cancer?, http://www.cancer.org/docroot/CRIcontent/CRI_2.4_
I x_WhatisCancer.asp?sitearea= (last visited Mar. 19, 2006) (on file with the McGeorge Law Review).
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2001.2 Half of all men and one-third of all women will develop this disease
during their lifetime.3 However, early detection and treatment can lengthen
patients' lives. In fact, if cancer is found early enough, it can often be cured
entirely.! As a result, medical professionals today face the complex problem of
determining how to detect cancer early enough to prevent the death, or at least
prolong the life, of a cancer victim.6 So, how can cancer be detected early enough
to prevent death or prolong life? One possible answer: nanotechnology.7
Scientists have recently developed a new technique involving the use of
nanoparticles to detect certain diseased molecules in the human body.' By
exposing human blood to nanoparticles that are covered with DNA and certain
antibodies, molecules that indicate specific human diseases can be revealed. 9
Accordingly, this application of nanotechnology can be used to detect certain
cancers, such as prostate cancer and breast cancer.'" While nanoparticle disease
detectors are not commercially marketable at this time," this application of
nanotechnology is merely an illustration of the many potential applications that
nanotechnology promises to provide.'2
Nanotechnology is predicted to trigger the next technological revolution.' 3 As
a result, the federal government and private industry provide billions of dollars
per year in nanotechnology research and development funds. 4 As with any
innovative commercial technology, nanotechnology inventors seek patent
protection in increasing numbers.'5
The grant of a patent by the United States Patent and Trademark Office gives
its owner the exclusive right to make, use, and sell the patented invention.' 6 If
2. Infoplease, Fifteen Leading Causes of Death in the U.S., 2001, available at http://www.infoplease.
conipa/AO005110.html (last visited Mar. 25, 2004) (on file with the McGeorge Law Review).
3. American Cancer Society, supra note 1.
4. Id.
5. American Cancer Society, Can Cancer Be Prevented?, http://www.cancer.org (last visited Mar. 25,
2004) (on file with the McGeorge Law Review).
6. See id. (describing ways to avoid getting cancer).
7. See John D. Schrock, Nanosphere 's Newest Detector Zeroes in on Specific Diseases, SMALL TIMES
(Jan. 7, 2004), available at http://www.smalltimes.com/document.display.cfm?documentid=7177 (copy on





12. See infra Part II.C (discussing the wide range of applications of nanotechnology).
13. See Michael P. Williams, Questions Abound About Patents and Nanotechnology, N.Y.L.J., Sept. 15,
2003, at T7 (raising the possibility that nanotechnology could develop the next business revolution just as
"railroads, radio, television, computers, biotechnology, and the Internet" did over the last two hundred years).
14. Bamaby J. Feder, Technology Briefing Nanotechnology: House Authorizes $2.36 Billion for
Research, N.Y. TIMES, May 8, 2003, at C4; Williams, supra note 13.
15. See Williams, supra note 13 (noting that as of September 2003, more than three thousand patents
have been issued to nanotechnology related inventions since 1996).
16. 35 U.S.C.A. § 154(a)(1) (West 2001).
McGeorge Law Review / Vol. 37
someone other than the patent owner uses the patented invention, he will often be
liable for patent infringement.17 However, prior to 2002, a common law defense
to patent infringement, known as the experimental use defense, allowed an
alleged infringer to escape infringement liability if his use was for non-
commercial experimental or research purposes. 8
Then, in Madey v. Duke University, the Court of Appeals for the Federal
Circuit virtually eliminated the experimental use defense by holding Duke
University liable for patent infringement based on the use of patented inventions
solely for experimental and research purposes." Since nanotechnology is
relatively new, and since there are billions of dollars in federal funding for
nanotechnology, much of the development of nanotechnology will be by way of
university-based research. ° Therefore, Madey has the potential to stifle the
development of nanotechnology by holding universities liable for patent
infringement or, more practically, by requiring universities to obtain licenses
from nanotechnology patent holders in order to avoid patent infringement.2 '
This Comment argues that the Federal Circuit's decision in Madey, by
virtually eliminating the experimental use defense to patent infringement, will
stifle the development of nanotechnology to the detriment of society 2 Part II
begins with a basic definition of nanotechnology and then details the
development of nanotechnology as a legitimate science in the late-twentieth
century 3 Part 11 goes on to discuss the practical applications of nanotechnology
and the patent rights available to nanotechnology inventions.2 Part III provides a
history of the judicially created experimental use defense to patent infringement
prior to Madey and then discusses the Federal Circuit's decision in Madey 5 Part
IV explains how an exceedingly narrow experimental use defense will stifle the
development of nanotechnology 6 Specifically, Part IV elucidates similarities
between arguments that have been made over the past two decades to protect
biotechnology innovation and arguments that can be made today to prevent the
stifling of nanotechnology 2
17. 35 U.S.C.A. § 271(a) (West 2001).
18. See infra Part III.B.
19. Madey v. Duke Univ., 307 F.3d 1351, 1362-63 (Fed. Cir. 2002).
20. See infra Part IV.
21. See infra Part IV.
22. See infra Part IV.
23. See infra Part IIA-B.
24. See infra Part H.C-D.
25. See infra Part IIl.
26. See infra Part IV.
27. See infra Part IV.
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II. NANOTECHNOLOGY
A. Definition(s)
The term "nanotechnology" is difficult to define precisely. Most
commentators define nanotechnology in either a general sense or a specific
sense. 28 In a general sense, nanotechnology refers to the branch of science that
deals with objects on the nanometer scale.29 A nanometer is one-billionth of a
meter.30 The nanometer scale thus involves very small objects that cannot be seen
by the naked eye." In a specific sense, nanotechnology refers to the process of
creating materials by specifically rearranging atoms or molecules at the
nanometer scale.32 In any event, under both the general definition and the specific
definition, nanotechnology essentially describes what nature has been doing since
the beginning of time: "making things atom by atom with just the right properties
to perform a specific function. 33
B. Background
The concept of nanotechnology was first introduced in 1959. 3" Richard
Feynman, a scientist and Nobel laureate, described his "ultimate vision" of
nanotechnology in a speech at the California Institute of Technology.35 As
28. See, e.g., Fredrick A. Fiedler & Glenn H. Reynolds, Legal Problems of Nanotechnology: An
Overview, 3 S. CAL. INTERDISC. L.J. 593, 595 (1994) (defining nanotechnology specifically as "manipulating
matter on an atom-by-atom or molecule-by-molecule basis to attain desired configurations"); Kelly Kordzik,
Small New World, NAT'L L.J., Dec. 16, 2002, at Cl (defining nanotechnology generally as "technology at the
nanoscale"); Barry Newberger, Intellectual Property and Nanotechnology, 11 TEX. INTELL. PROP. L.J. 649, 650
(2003) (defining nanotechnology generally as "the application of science at the nanoscale"); Joel Rothstein
Wolfson, Social and Ethical Issues in Nanotechnology: Lessons From Biotechnology and Other High
Technologies, 22 BIOTECHNOLOGY L. REP. 376, 376 (2003) (defining nanotechnology both generally and
specifically as "the creation of molecule-size machines and other devices and the manipulation of substances
molecule by molecule"); Wei Zhou, Ethics of Nanobiotechnology at the Frontline, 19 SANTA CLARA
COMPUTER & HIGH TECH. L.J. 481, 482 (2003) (defining nanotechnology generally as "the science and
technology pertaining to visualization, manipulation, and control of materials at the nanometer scale");
Williams, supra note 13 (defining nanotechnology specifically as involving "the methods and processes that
create materials by specifically rearranging atoms or molecules at the nanometer scale").
29. Zhou, supra note 28, at 482.
30. Kordzik, supra note 28; see also R. Colin Johnson, Descending From the Micro- to Nano-scale
Electronics Promises to Extend Moore's Law Indefinitely---Nanotechnology Is Rebuilding Electronics One
Atom at a Time, ELECTRONIC ENGINEERING TIMES, Sept. 16, 2002, at A55 (noting that "nano" derives from the
Greek word for "dwarf").
31. Kordzik, supra note 28. To put in perspective just how small the nanometer scale is, consider the
following examples. The diameter of a human hair is 80,000 nanometers, which is enormous on the nanometer
scale. On the other hand, an atom is slightly smaller ihan a nanometer. A nanometer is roughly the width of four
atoms. Id.
32. Fiedler & Reynolds, supra note 28, at 595.
33. Kordzik, supra note 28.
34. Johnson, supra note 30.
35. Id.
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Feynman prophetically suggested, "[tihe principles of physics, as far as I can see,
do not speak against the possibility of maneuvering things atom by atom."36
Feynman's concept of molecular manipulation was innovative indeed. In
fact, Feynman's idea did not gain acceptance in the scientific community for
quite some time; instead, it provoked an abundance of science fiction literature
regarding nanotechnology.3 Science fiction authors surmised that nearly all
devices could be created by microscopic robots working one atom at a time. 8
Some even hypothesized about an ultimate human catastrophe, called the Gray
Goo catastrophe, in which self-replicating robots would multiply out of control
and destroy humanity. While some still believe nanotechnology has this
inherent devastating potential,40 the scientific community eventually embraced
nanotechnology as a legitimate science.
In the early 1980s, scientific breakthroughs in nanotechnology at last
emerged." Researchers developed a technique called scanning probe microscopy,
which allows for the arrangement of single atoms into particular molecular
configurations.4 2 This breakthrough, which permits scientists to manipulate single
atoms, spurred scientific literature that explored the possibilities of nanotechnology.43
36. Fiedler & Reynolds, supra note 28, at 597 (quoting Richard Feynman).
37. See Johnson, supra note 30 (discussing science fiction authors' speculations).
38. Id.
39. Bamaby J. Feder, Nanotechnology Has Arrived: A Serious Opposition is Forming, N.Y. TIMES,
Aug. 19, 2002, at C3.
40. See Ralph C. Merkle, Nanotechnology: What Will It Mean?, IEEE SPECTRUM, Jan. 2001, at 19
(pointing out that two notable commentators, Eric Drexler and Bill Joy, have discussed the potential problems
of nanotechnology). In 2000, Bill Joy, the cofounder and chief scientist of Sun Microsystems, wrote a
controversial article that spurred much discussion throughout the scientific community. Bill Joy, Why the
Future Doesn't Need Us, WIRED MAG., Apr. 2000, available at http://www.wired.comwired/archive/8.04/joy
_pr.html (on file with the McGeorge Law Review). Joy argued that the combination of twenty-first century
technologies, consisting of robotics, genetic engineering, and nanotechnology, "are threatening to make humans
an endangered species." Id. Joy's forecast for the future of technology was influenced by his career as a
computer scientist, his general interest in technology, and his substantial review of technology literature (which,
interestingly enough, included a discussion of Theodore Kacynski's Unabomber Manifesto). Id. Regarding
nanotechnology, Joy proclaimed:
Unfortunately, as with nuclear technology, it is far easier to create destructive uses for
nanotechnology than constructive ones. Nanotechnology has clear military and terrorist uses,
and you need not be suicidal to release a massively destructive nanotechnological device-
such devices can be built to be selectively destructive, affecting, for example, only a certain
geographical area or a group of people who are genetically distinct.
Id. Joy goes on to describe that the ultimate problem with nanotechnology, as well as with genetics and
robotics, is that it has the power of destructive self-replication. Id. This self-replication argument has been
rebutted by other commentators. See Merkle, supra, at 20 (pointing out that while nanotechnology will indeed
use self-replication, it will not replicate living systems and therefore will not be able to self-replicate beyond
human control in the way that a biological self-replicating system can). Ultimately, Joy proposes that the only
realistic alternative to the possible destruction of humanity is to limit the pursuit of certain types of knowledge.
Joy, supra.
41. Johnson, supra note 30.
42. See id. Scanning probe microscopy is comprised of two distinct tools: the scanning tunneling
microscope and the atomic force microscope. Id.
43. For example, Eric Drexler popularized the term "nanotechnology" in his seminal 1986 book,
Engines of Creation. Id.
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This literature included nanotechnology pioneer Eric Drexler's proposal for an
innovative manufacturing technology called bottom-up manufacturing."
Traditional manufacturing processes employ top-down manufacturing. 5 Top-
down manufacturing essentially means that one takes larger objects and makes
smaller objects out of them.46 For example, creating a sculpture from a large block of
stone is a primitive type of top-down manufacturing. The sculptor must chisel, grind,
shape, and sand the block of stone until he obtains the desired configuration. This
process results in significant wasted stone and potentially damaging environmental
effects from chiseling, grinding, shaping, and sanding the block.
Bottom-up manufacturing, conversely, takes smaller objects and creates
larger objects. 47 The smaller objects can be individual atoms and molecules. By
multiplying and manipulating these atoms and molecules in a particular way, one
can create a desired object.4s Living organisms, such as plants or human beings,
are essentially created in this manner. 9 In the sculpture example, the same
sculpture could be created using bottom-up manufacturing. If created in this
manner, the sculpture would have all of its unique characteristics without any
wasted stone or environmentally harmful manufacturing techniques °
The next major development in nanotechnology came in 1991 with the
discovery of carbon nanotubes.5' A carbon nanotube is a "strawlike structure with
a one-atom-thick wall of carbon atoms."52 When multiplied, carbon nanotubes
create a strong material that some expect to replace steel and aluminum as the
fundamental material out of which many everyday objects and structures are
composed. 3 One problem with carbon nanotubes is their high costi- Presently, it
44. Fiedler & Reynolds, supra note 28, at 596-97.
45. Id.
46. Id.; see also Johnson, supra note 30 (defining top-down as "the building of materials and devices by
carving, molding, or machining bulk materials with tools and lasers").
47. Fiedler & Reynolds, supra note 28, at 596; see also Johnson, supra note 30 (defining bottom-up as
"the construction of devices starting with individual atoms").
48. Fiedler & Reynolds, supra note 28, at 596.
49. See id. (describing how a human body begins as a single cell, an ovum, and grows into
approximately 75 trillion cells, a mature human being).
50. See generally Rocky Angelucci, A Beginner's Guide to Nanotechnology, DALLAS Bus. J., Sept. 10,
2001, available at http://dallas.bizjoumals.comdallas/stories/200l/09/10/focus2.htnml (describing the trans-
formation from today's manufacturing techniques to nanotechnology manufacturing techniques as "crude,
inefficient, polluting factories into factories able to build many different things with little or no modification
economically and cleanly").
51. Behfar Bastani & Dennis Fernandez, Intellectual Property Rights In Nanotechnology, INTELL. PROP.
TODAY, Aug. 2002, at 36.
52. Angelucci, supra note 50; see also Johnson, supra note 30 (defining carbon nanotubes as "cylinders
as small as 1 [nanometer] in diameter grown from fullerenes to resemble a rolled-up sheet of graphite").
53. Angelucci, supra note 50. In fact, as pointed out by one commentator, a carbon nanotube "is
structurally 100 times stronger than steel of the same weight." Johnson, supra note 30.
54. Angelucci, supra note 50.
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is significantly more expensive to produce carbon nanotubes than to produce
steel or aluminum. 5
Since 1997, federal funding for research and development in nanotechnology
in the United States has increased significantly.56 Some notable politicians began
to promote nanotechnology and its potential to become the next major
technological breakthrough.57 President Bill Clinton began federal funding of
nanotechnology research and development by creating the National
Nanotechnology Initiative."8 In May 2003, the House of Representatives
approved a bill that would provide $2.36 billion for nanotechnology research and
development over the next three years.59 With federal funding for nanotechnology
in the billions,6° the science will undoubtedly continue to grow and develop in the
coming years. Nanotechnology is currently on the forefront of technology and
could provide the next technological revolution.6
55. See id. (noting that "nanotubes are still too expensive to use in everyday construction materials").
Angelucci also notes that the cost of producing carbon nanotubes has decreased significantly in recent years and
predicts that manufacturers will develop broad uses for carbon nanotubes in the near future. Id.
56. See National Nanotechnology Initiative, Frequently Asked Questions, http://www.nano.gov/html/
facts/faqs.html (last visited Mar. 25, 2004) (on file with the McGeorge Law Review) (stating that in fiscal year
1997 federal funding of nanotechnology research and development was $116 million).
57. For example, former speaker of the U.S. House of Representatives Newt Gingrich is a strong
advocate of nanotechnology. Steve Crosby, Newt Goes Nano: Ex-House Speaker Named to Science/Business
Alliance, SMALL TIMES, (Dec. 13, 2001), available at http://www.smalltimes.com/document-display.
cfm?document _id=2728. Gingrich believes that nanotechnology can lead to major breakthroughs in medicine,
computers, manufacturing, and the environment. In addition, he believes that tremendous wealth will be
generated by nanotechnology in the near future. As a result, Gingrich has argued heavily for increased
governmental funding for nanotechnology. Id. In fact, Gingrich has even proposed government-funded
monetary rewards for privately invented nanotechnology inventions. See Newt Gingrich, National Woes?
Dangle Prizes, Solutions Will Follow, USA TODAY, Jan. 21, 2002, at I IA (arguing that by the government
offering prizes, inventors would make scientific breakthroughs sooner).
58. Feder, supra note 14. The National Nanotechnology Initiative (NNI) is a federal research and
development program that was created to centralize federal agency efforts in nanoscale science, engineering,
and technology. National Nanotechnology Initiative, About the NNI, http://www.nano.gov/htmUabout/
homeabout.html (last visited Mar. 25, 2004) (on file with the McGeorge Law Review). The NNI consists of
sixteen federal agencies of which ten have research and development budgets for nanotechnology. Id. The
NNI's goals are the following: "(1) conduct R&D to realize the full potential of this revolutionary technology;
(2) develop the skilled workforce and supporting infrastructure needed to advance R&D; (3) better understand
the social, ethical, health, and environmental implications of the technology; and, (4) facilitate transfer of the
new technologies into commercial products." Id. Thus far, the federally funded programs that are a part of the
NNI have seen much advancement in nanotechnology, including developments involving semiconductor
nanocrystals, nano-electro-mechanical sensors, and nanotube-based fibers. Id.
59. Feder, supra note 14.
60. Some commentators have argued, however, that the federal government should spend much more on
nanotechnology research than is currently being spent. See, e.g., Kevin Maney, Tiny Technology That Could:
Nanotech Could Solve Oil Issues, USA TODAY, Oct. 1, 2003, at 3B (arguing that Congress should spend $20
billion a year on energy-related nanotechnology research in order to lessen the United States' dependence on
Middle Eastern oil).
61. See Williams, supra note 13.
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C. Applications
Nanotechnology has broad applications. Since nanotechnology is essentially
the concept of making things smaller, it has the potential to affect nearly all
aspects of our lives.62 Some specific areas where nanotechnology is expected to
be beneficial include the following: consumer products, 63 manufacturing and the
environment,6 energy,61 the military,66 medicine,67 computer hardware, 68 and
space travel.69
The most noticeable application of nanotechnology to the ordinary person
will be in the area of consumer products. Several products currently available on
the market utilize nanotechnology. Clothing retailer Eddie Bauer uses nanofibers
in its innovative stain- and wrinkle-resistant pants.7 In addition, sunscreen
manufacturers have employed nanotechnology to create sunscreens that block
harmful ultra-violet light.7' Products that are soon expected to employ
62. See generally Merkle, supra note 40, at 19 (discussing the impact nanotechnology will have on
society).
63. See discussion infra notes 70-74 and accompanying text (discussing consumer products).
64. See discussion infra notes 75-84 and accompanying text (discussing manufacturing and the
environment).
65. See discussion infra notes 85-89 and accompanying text (discussing energy).
66. See discussion infra notes 90-97 and accompanying text (discussing the military).
67. Nanotechnology is predicted to assist in many facets of medicine. For example, nano-sized biochips
could be inserted into the human body in order to detect diseased cells. Fiedler & Reynolds, supra note 28, at
601 (discussing devices that "would have dramatic implications for the practice of medicine"). Nanoparticles
could be ingested in order to deliver drugs to predetermined areas of the human body with exact precision.
Michael Becker, At Nanoscale, the Laws of Humans May Not Apply, (July 30, 2001) available at http://www.
smalltimes.com/document -display.cfm?documentjid=1798 (noting that certain medical applications will
require regulators to carefully consider how to monitor these devices); Zhou, supra note 28, at 484 (discussing
the application of biochips in the area of medical diagnostics). In addition, nanodevices could actually repair
cells damaged by aging, or even destroy diseased cells, such as cancer cells. Fiedler & Reynolds, supra note 28,
at 601.
68. In recent years, computer chips have become significantly smaller while at the same time have been
able to process an increasing amount of information. It is estimated that today's computer chips contain 40
million transistors. It is predicted that nanotechnology will enable scientists to create even smaller chips that are
capable of holding trillions of transistors. The end result would be faster and much more powerful computing
systems than are currently available. See Merkle, supra note 40, at 19 (discussing computer hardware
innovations); Julia A. Moore, The Future Dances on a Pin's Head; Nanotechnology: Will It Be a Boon - Or
Kill Us All?, L.A. TIMES, Nov. 26, 2002, at B 13 (discussing developments in computer chips).
69. NASA currently employs a 60-scientist nanotechnology team at its Ames Research Center located in
Silicon Valley. A primary focus of the nanotech team is to create a spacecraft that has enough computing power
on board so that it would not be entirely controlled from Earth. Nanotechnology has the potential of creating
smaller and lighter computing that could make NASA's goal a reality. This accomplishment could conceivably
allow NASA to send the first manned mission to Mars. See Ariana Eunjung Cha, Big Potential From Small
Things, WASH. POST, Mar. 21, 2002, at El (discussing NASA's interest in nanotechnology).
70. Bernadette Tansey, Molecular Might: Nanotech "Battle Suits" Could Amplify Soldiers' Powers,
S.F. CHRONICLE, Apr. 7, 2003, at El.
71. Edward Epstein, Silicon Valley Pins Hopes on Nanotechnology Boom: U.S. Ready to Spend Billions
on Revolutionary Science, S.F. CHRONICLE, May 8, 2003, at Al.
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nanotechnology include cosmetics,72 scratch-resistant eyeglass lenses,73 and big-
screen televisions.4
Perhaps the most revolutionary application of nanotechnology will be in the
areas of manufacturing and the environment. Manufacturing will no doubt be
transformed by what is sometimes called parallel assembly.75 Parallel assembly is
a process in which individual atoms, controlled by computers, self-replicate to
create larger structures. 76 The process begins with a single nanosized robotic arm
being instructed to make identical copies of itself so that within a short period of
time millions of robotic arms are created.77 Each robotic arm has a "sticky" arm
capable of manipulating individual atoms.78 The composition of robotic arms
could then be told to build a particular product by using its "sticky" arms to
maneuver and rearrange millions of atoms at a time.79 Parallel assembly is the
method by which bottom-up manufacturing would be possible.s
Bottom-up manufacturing would eliminate many of the environmentally
damaging effects inherent in traditional manufacturing methods. 8,
Nanotechnology promises additional benefits to the environment, however. For
example, water filtration systems could be designed at the molecular level, which
would result in cleaner drinking water.82 Natural gas pipelines could also be
designed at the molecular level, which would result in cleaner burning.83
Nanoparticles could also be used as sensors to monitor air and water for
particular toxic substances.4 In sum, the combination of nanotechnology's
beneficial environmental effects and enhanced manufacturing capabilities will
likely be some of its most promising applications.
72. See National Nanotechnology Initiative, Applications/Products, http://www.nano.gov/html/facts
appsprod.html (last visited Mar. 25, 2004) (on file with the McGeorge Law Review) (stating that cosmetics
involving nanotechnology are available today).
73. Id.
74. See Kevin Maney, Finally a Purpose for Nanotech to Turn on Average Joe: Big-screen TVs, USA
TODAY, July 9, 2003, at 3B (describing Nano Emissive Display, which Motorola is expected to use within three
years to create 50-inch-wide flat-screen televisions that will cost consumers less than $1000).
75. Commentators have used different terms to describe essentially the same manufacturing process.
See, e.g., Merkle, supra note 40, at 21 (using the term "exponential assembly"); Angelucci, supra note 50 (using
the term "parallel assembly"); Maney, supra note 74 (using the term "self-assembly").
76. Angelucci, supra note 50.
77. Id.
78. Id.
79. Id. Some critics of nanotechnology and self-replication have argued that the robotic arms could
become out of control and replicate themselves at will. However, this theory has been struck down by many
scientists. See, e.g., Merkle, supra note 40, at 19-21 (pointing out that computer controlled self-replication is
distinct from biological self-replication in that computer controlled self-replication can be stopped at any time
by humans simply by disconnecting the robotic arms' power supply).
80. See supra text accompanying notes 47-50 (discussing bottom-up manufacturing).
81. See supra text accompanying notes 47-50 (discussing bottom-up manufacturing and its lack of
environmentally harmful manufacturing techniques).
82. Jim Krane, Nanoparticles: The Best Thing Since Plastic?, SEATTLE TIMES, Sept. 9, 2002, at C3.
83. Id.
84. Id.
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Nanotechnology may also have important implications in the energy
industry. One commentator notes that nanotechnology "has the potential to make
solar energy viable on a massive scale, allow hydrogen and methane to replace
gasoline in cars, and make vehicles and planes far lighter so they use less fuel."85
Currently, solar energy is an expensive form of energy; however, it is expected
that nanotechnology could reduce the cost of making solar panels and thus allow
solar energy to enter the mainstream market 6 Replacing gasoline with
alternative fuel sources would decrease oil consumption and in turn decrease
foreign oil dependency, which would not only have economic benefits for the
United States but would offer political benefits as well.87 As discussed
previously,88 nanotechnology will likely create stronger and lighter materials,
thus allowing less fuel consumption in common modes of transportation, such as
automobiles and airplanes.89
Nanotechnology also has important applications to the military. Already, the
Massachusetts Institute of Technology (MIT) has created the Institute of Soldier
Nanotechnologies (the Institute), which is funded by a five-year Army grant of
$50 million.9° MIT professors working in the Institute anticipate significantly
improving a soldier's gear through the use of nanotechnology. 9' Some ideas that
are currently being researched and designed include the following: waterproof
Kevlar vests with a layer of one-molecule thick flouropolymer, self-protecting
clothing that can harden on command, and simulated muscles made of polymer
fibers that will assist soldiers in carrying heavy loads.92 In addition to university-
based research, private companies are also exploring applications that
nanotechnology might have in the context of the military.93 For example,
Nanosys Inc. is developing thermoelectric devices that could be used to enable a
soldier to send signals to other soldiers and devices that provide self-cooling
systems for soldiers.94 Each of these applications has the vital utility of increasing
a soldier's capabilities while at the same time decreasing, or at least not
significantly increasing, the weight of a soldier's gear.95 Admittedly, many of
these nanotechnology devices are in their early stages of development and may
not be available for many years.96 However, if made available, the scope of these
85. Maney, supra note 60.
86. Id.
87. Id.
88. See supra notes 51-55 and accompanying text (explaining how carbon nanotubes will lead to
stronger and lighter materials).
89. Maney, supra note 60.
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devices is expected to extend beyond the military and include applications for
police officers, firefighters, and emergency personnel.97
D. Patent Law and Nanotechnology
In the United States, patent rights were first recognized in the Constitution.98
The framers granted Congress the explicit power "[t]o promote the Progress of
Science and useful Arts, by securing for limited Times to Authors and Inventors
the exclusive Right to their respective Writings and Discoveries."99 Congress
exercised this power by enacting the Patent Act of 1790. '00 A subsequent version
of this legislation, the Patent Act of 1952, is the modem statutory authority for
patent rights in the United States.'' The United States Patent and Trademark
Office (USPTO), a federal agency within the Department of Commerce, is
responsible for granting and issuing patents to inventors.'0 2
A patent 10 3 gives its owner the legal right to exclude others from making,
using, or selling his patented invention.'' While a patent owner enjoys exclusive
rights to his patented invention, an inventor must first meet stringent statutory
requirements in order to obtain patent protection from the USPTO.'0° First, the
inventor must demonstrate that the type of invention sought to be patented falls
within the statutory definition of patentable subject matter.'0 Patentable subject
matter is a low threshold requirement and is broadly defined to include any
"process, machine, manufacture, or composition of matter.' 0 7
Once the patentable subject matter hurdle is overcome, the inventor must
then satisfy several fundamental statutory elements required to obtain a patent.
0 8
97. Id.
98. U.S. CONST. art. I, § 8, cl. 8.
99. Id.
100. Graham v. John Deere Co., 383 U.S. 1, 6 (1966). The Patent Act was amended by Congress nearly
fifty times between 1790 and 1950. Id. at 10.
101. See 35 U.S.C.A. §§ 1-376 (West 2001) (addressing patents); Graham, 383 U.S. at 12-17
(discussing the 1952 Patent Act with a particular focus on the nonobviousness requirement).
102. See 35 U.S.C.A. § I (West 2001) (establishing the USPTO); 35 U.S.C.A. § 2 (West 2001) (listing
the general powers and duties of the USPTO).
103. Throughout this comment I will use the term "patent" to refer to a utility patent, which is the most
crmnon type of patent the USPTO grants. Two other types of patents, a design patent and a plant patent, are
also granted by the USPTO.
104. 35 U.S.C.A. § 271(a) (West 2001); see infra text accompanying notes 121-22 (discussing patent
infringement).
105. 35 U.S.C.A. §§ 101-03.
106. See 35 U.S.C.A. § 101 (West 2001) (describing patentable inventions).
107. Id. The design of a manufactured item also falls within the definition of patentable subject matter.
See id. § 171 (defining a design patent as an "ornamental design for an article of manufacture"). In addition, a
plant falls within patentable subject matter. See id. § 161 (defining a plant patent as a "distinct and new variety
of plant").
108. See id. §§ 101-03 (describing patentable inventions and the conditions of patentability).
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The invention must be shown to be useful, novel, and nonobvious.' °9 First, the
utility requirement of section 101 mandates that an invention be put toward some
useful purpose." Second, and more difficult to comply with in many cases, is the
novelty requirement of section 102, which requires that an invention be new."'
The novelty requirement mandates that the invention be different from any
previously developed and recognized technology. ' 12 Third, the nonobviousness
requirement of section 103 requires that the invention not be "obvious at the time
the invention was made to a person having ordinary skill in the art.""' 3 In addition
to these three statutory elements, the inventor must also disclose how to make the
invention, how to use the invention, and the best mode of carrying out the
invention.''
4
If an inventor satisfies the statutory requirements, the USPTO will issue a
patent for a term of twenty years from the date the patent application was filed."5
Once a patent is awarded to an inventor, a contract essentially has been created
between the patent owner and society." 6 The patent owner enjoys the right to
exclude others from making, using, and selling the invention."7 Society, on the
other hand, now has access to the full disclosure of how to use and make the
patented invention."8 Ideally, this quid pro quo arrangement is beneficial both to
the patent owner and to society. The inventor has a significant monetary
incentive to obtain patent protection of a new technology and society has a need
to promote and encourage rapid technological development,"9 just as the framers
envisioned.'20
One who impedes a patent owner's exclusive right to make, use, or sell the
patented invention is generally liable to the owner for patent infringement.' 2 ' It is
important to note that since a patent merely grants the right to exclude others
from infringing on a patent owner's invention, a patent owner must affirmatively
109. Id.
110. Id. § 101.
111. Id. § 102.
112. Id.
113. Id. § 103(a).
114. Id. § 112.
115. 35 U.S.C.A. § 154(a)(2) (West 2001).
116. See Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights and Experimental
Use, 56 U. CHI. L. REV. 1017, 1024-36 (1989) (discussing the exclusive rights an inventor gets in exchange for
an invention and its corresponding disclosure).
117. 35 U.S.C.A. § 271(a) (West 2001).
118. See Eisenberg, supra note 116, at 1028-30 (discussing an inventor's incentive to disclose the
contents of his invention).
119. See id. at 1024-30 (discussing the exclusive rights an inventor gets in exchange for an invention
and its corresponding disclosure).
120. See U.S. CONST. art. I, § 8, cl. 8 (granting Congress the power "[t]o promote the Progress of
Science and Useful Arts").
121. 35 U.S.C.A. § 271.
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For the most part, nanotechnology falls within patentable subject matter and
thus a nanotechnology invention can be patented so long as the other statutory
requirements are met. 23 Some commentators have raised the idea that
nanotechnology inventions should not be patentable.'2 4 Nanotechnology, so the
argument goes, is essentially the process of making existing technology
smaller.' ' Making something smaller is not in itself patentable since the
nonobviousness requirement of section 103 will not be met. 26 While this
argument has intuitive appeal, it is flawed in the context of nanotechnology since
creating existing technology on the nanoscale will often change the properties
and characteristics of a particular invention."7 For example, quantum dots are
semiconductor nanostructures that have different properties than typical
semiconductors. 8 Quantum dots have exceptional optical properties, based on
their size, that are not found in typical semiconductors. Therefore, quantum dots
are highly desired in certain industries. 9 At this point, despite a lack of case law
regarding nanotechnology patents, it seems nanotechnology will be the newest
major technology deemed patentable, following the lead of biotechnology,'
30
computer software, 3' and business methods.'
3 2
Recently, the USPTO has experienced a surge in patent applications for
nanotechnology inventions or for inventions containing some nanosized
component. 13 In fact, some commentators have argued that the surge in nano-
technology patent applications has resulted in the USPTO being inadequately
trained to handle the relatively new scientific area of nano-technology.' 34
122. See id. § 271(e)(4) (prescribing the remedies available to a patent owner); see generally 3 JOHN
GLADSTONE MILLS II ET AL., PATENT LAW FUNDAMENTALS § 18:3 (2003) (discussing the general nature of
patent infringement actions).
123. See 35 U.S.C.A. § 101 (defining patentable subject matter to include any "composition of matter").
124. See Williams, supra note 13 (discussing whether nanotechnology should be patentable subject
matter).
125. Id.




130. See Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980) (holding that an artificially created oil-
eating bacterium is patentable subject matter).
131. See Diamond v. Diehr, 450 U.S. 175, 191-93 (1981) (holding that a molding process which utilized
a mathematical formula and a programmed digital computer is patentable subject matter).
132. See State St. Bank & Trust Co. v. Signature Fin. Group, Inc., 149 F.3d 1368, 1373 (Fed. Cir. 1998)
(holding that a data processing system used in multi-tiered partnership fund services is patentable subject
matter).
133. See Williams, supra note 13 (stating that more than three thousand patents had been issued to
nanotechnology-related applications between 1996 and 2003).
134. Doug Brown, U.S. Patent Examiners May Not Know Enough About Nanotech, SMALL TIMES, (Feb.
4, 2002) available at http://www.smalltimes.com/document-display.cfm?document_id=3035 (noting that some
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However, private institutions are actively offering assistance to the USPTO as to
how it can improve the nanotechnology patent process, and the USPTO seems to
be taking active steps to properly train examiners in nanotechnology.'35 As a
result, a significant number of nanotechnology-related patents have already been
granted.'36 One commentator notes that as of September 2003, "more than 3000
patents [have been] issued to nanotechnology-related applications since 1996.' ' 7
This recent trend demonstrates that nanotechnology-related patents will continue
to increase in the coming years.
As the USPTO increasingly grants nanotechnology patents, infringement of
nanotechnology patents will no doubt increase as well. Therefore, it can be
anticipated that owners of nanotechnology patents will enforce their right to
exclude others from making, using, or selling their nanotechnology inventions by
bringing claims for patent infringement. As a result, alleged infringers will likely
look to defenses to patent infringement in order to escape liability. A specific
exception to patent infringement, known as the experimental use defense, is
discussed in the following section.
III. THE EXPERIMENTAL USE DEFENSE TO PATENT INFRINGEMENT
A. Background
Statutory law clearly defines what activity constitutes patent infringement.
3 8
Patents in general are addressed in Title 35 of the United States Code.3 9 The
rights granted to a patent owner are spelled out in section 154, which states that
"[e]very patent shall contain.., a grant to the patentee.., of the right to exclude
others from making, using, .... or selling the invention. ' '"' ° Infringement is
addressed in section 271, which states that "whoever without authority makes,
uses, .... or sells any patented invention... infringes the patent.', 14 ' Therefore,
experts believe the "U.S. patent examiners must become better educated about nanotechnology if the
burgeoning industry is going to fully thrive").
135. On November 8, 2001, the Foresight Institute, a nonprofit organization with the goal of guiding
emerging technologies to the benefit of society with a particular focus on nanotechnology, hosted a
nanotechnology patent roundtable. Foresight Institute, Nanotechnology Patent Roundtable, http://www.
foresight.org/Conferences/MNT9/Patents.html (last visited Mar. 25, 2004) (on file with the McGeorge Law
Review). The meeting was expected to draw a wide range of people, including senior USPTO officials, patent
attorneys, nanotechnology industry leaders, and law school faculty members. Id. The planners expected the
discussion to include "the possibility of creating a special classification for nanotechnology patent applications,
a creation of a database of nanotechnology related prior art and a creation of a nanotechnology industrylUSPTO
partnership to provide training for patent examiners in the current topics of nanotechnology." Id.
136. Williams, supra note 13.
137. Id.
138. See 35 U.S.C.A. § 271 (West 2001) (addressing infringement of patent).
139. See id. §§ 1-376 (addressing patents).
140. Id. § 154(a)(1).
141. Id. § 271(a).
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according to the language of the statute, any making, using, or selling of a
patented invention constitutes infringement."'
The only statutory exception to patent infringement is a narrow one that can
only be used in the context of pharmaceuticals.' 3 In 1984, Congress created an
exception for generic drug manufacturers enabling them to conduct tests on near-
expired patented drugs in order to obtain Food & Drug Administration
approval.'" Outside of this narrow exception, though, an alleged infringer has no
statutory argument that his making, using, or selling of another's patented
invention is justifiable. 145 Therefore, an alleged infringer must turn to the
common law in search of defenses to patent infringement.
The experimental use defense to patent infringement has been recognized in
the common law for nearly 200 years. 1 6 However, after all this time, there is a
remarkably small amount of case law discussing the experimental use defense.' 7
The scarcity of existing judicial opinions most likely has to do with the nature of
experimental use. Using an invention for experimental purposes, such as an
independent inventor testing the disclosure of a patent or a public university
testing a patented invention for academic purposes, often does not involve
commercialization.'4 8  The primary reason that a patent owner brings an
infringement action, on the other hand, is to redress some sort of violation of the
patent owner's commercial interests.'4 9 Since a patent owner does not necessarily
have monetary incentives to litigate noncommercial, experimental infringement
of his patent, few experimental use cases are in fact litigated.'5° In these relatively
few cases that do involve the experimental use defense, the defense has rarely
enabled the alleged infringer to escape liability for patent infringement." '
142. See generally MILLS, supra note 122, § 18:3 (discussing patent infringement in general and stating
that one of the elements of a prima facie case of patent infringement is that the plaintiff introduce "evidence that
the defendant has engaged in any of the activities proscribed by 35 U.S.C.A. § 271").
143. See 35 U.S.C.A. § 271(e)(1). "It shall not be an act of infringement to make, use .... or sell...
solely for uses reasonably related to the development and submission of information under a Federal Law which
regulates the manufacture, use, or sale of drugs." Id.
144. See Suzanne T. Michel, Comment, The Experimental Use Exception to Infringement Applied to
Federally Funded Inventions, 7 HIGH TECH. L.J. 369, 375-76 (1992) (discussing this exception, which was part
of the Drug Price Competition and Patent Term Restoration Act of 1984).
145. See id. at 369 (stating, "[w]ith one minor exception the patent statutes do not suggest any instance
in which use of a patented invention is not infringement").
146. See infra text accompanying note 154 (stating that courts first recognized the experimental use
defense in 1813).
147. See Ronald D. Hantman, Experimental Use as an Exception to Patent Infringement, 67 J. PAT. &
TRADEMARK OFF. SOC'Y 617, 624 (1985) (stating that there have been only about twenty-nine cases involving
the experimental use defense since it was first recognized in 1813).
148. See Lauren C. Bruzzone, The Research Exemption: A Proposal, 21 AM. INTELL. PROP. L. ASS'N
Q.J. 52, 57 (1993) (explaining why few defendants prevail in asserting the experimental use defense).
149. Id.
150. Id.
151. See infra note 166 (stating that only seven cases have allowed the experimental use defense); see
also 5 DONALD S. CHISUM, CHISUM ON PATENTS § 16.03[1][b] (2002) (discussing lower court decisions prior to
1983).
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B. The Common Law: Developing a Narrow Experimental Use Defense
The experimental use defense to patent infringement' s2 was first enunciated in
the early nineteenth century by Justice Joseph Story, a member of the United
States Supreme Court and an influential jurist in the area of patent law.'53 Justice
Story, while a member of the Massachusetts Circuit Court, first mentioned the
concept of experimental use in the 1813 case of Whittemore v. Cutter.' In
approving a jury instruction that went against the defendant in an infringement
action, Justice Story explained that "it could never have been the intention of the
legislature to punish a man, who constructed such a machine merely for
philosophical experiments, or for the purpose of ascertaining the sufficiency of
the machine to produce its described effects."'55 That same year, in Sawin v.
Guild, Justice Story clarified the holding of Whittemore.16 He stated that "the
making of a patented machine to be an offence within the purview of it, must be
the making with an intent to use for profit, and not for the mere purpose of
philosophical experiment, or to ascertain the verity and exactness of the
specification.', 57 Synthesizing Whittemore and Sawin, Justice Story developed an
experimental use defense to patent infringement that would turn on whether the
alleged infringer had a commercial intent when infringing on another's patent.' s
If the alleged infringer had a commercial intent, then patent infringement liability
would be proper. If, however, the alleged infringer did not have a commercial
intent, then liability for patent infringement could be avoided.
Some courts applied Justice Story's defense in the nineteenth century. 9 In
1861, the court in Poppenhusen v. Falke declared that it is "now well settled, that
an experiment with a patented article for the sole purpose of gratifying a
philosophical taste, or curiosity, or for mere amusement, is not an infringement
of the rights of the patentee." '6 The next noteworthy articulation of the
152. The "experimental use defense to patent infringement" is not the same as the "experimental use
exception" to the on sale bar of 35 U.S.C.A. § 102(b). Tom Saunders, Renting Space on the Shoulders of
Giants: Madey and the Future of the Experimental Use Doctrine, 113 YALE L.J. 261, 261 n.1 (2003). Since
each legal doctrine uses the term "experimental use," the doctrines are sometimes confused. The experimental
use exception to the on sale bar of 35 U.S.C.A. § 102(b) has nothing to do with patent infringement. See 1
MILLS, supra note 122, § 8:10 (discussing experimental use in the context of 35 U.S.C § 102(b)). Rather, the
experimental use exception operates to not prevent an inventor from obtaining a patent on an invention that was
sold for certain experimental uses that would otherwise violate the requirement that an invention cannot be "on
sale" for "more than one year prior to the date of the application for patent." Id. §§ 8:8, 8:10.
153. See 5 CHISUM, supra note 151, § 16.03[1][a] (discussing the historical development of the
"experimental purpose" limitation on infringement).
154. 29 F. Cas. 1120 (C.C.D. Mass. 1813) (No. 17,600).
155. Id. at 1121.
156. 21 F. Cas. 554 (C.C.D. Mass. 1813) (No. 12,391).
157. Id. at 555.
158. Janice M. Mueller, No "Dilettante Affair": Rethinking the Experimental Use Exception to Patent
Infringement for Biomedical Research Tools, 76 WASH. L. REV. 1, 20 (2001).
159. Bruzzone, supra note 148, at 56.
160. 19 F. Cas. 1048, 1049 (C.C.S.D.N.Y. 1861) (No. 11,279).
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experimental use defense was by William C. Robinson in his influential 1890
treatise.16' Summarizing the existing law at the time, Robinson stated:
An unauthorized sale of the invention is always such an act. But the
manufacture or the use of the invention may be intended only for other
purposes, and produce no pecuniary result. Thus where it is made or used
as an experiment, whether for the gratification of scientific tastes, or for
curiosity, or for amusement, the interests of the patentee are not
antagonized, the sole effect being of an intellectual character in the
promotion of the employer's knowledge or the relaxation afforded to his
mind. But if the products of the experiment are sold, or used for the
convenience of the experimentor, or if the experiments are conducted
with a view to the adaptation of the invention to the experimentor's
business, the acts of making or of use are violations of the rights of the
inventor and infringements of his patent.
62
Although some commentators have criticized Robinson's statements
regarding the experimental use defense,' 63 courts have consistently approved of
his formulation.'9
The common law experimental use defense described above was applied by
some courts in the twentieth century.' 65 Ruth v. Steams-Roger Mfg. Co. was one
of the few cases in which the alleged infringer successfully asserted the
defense.'" In Ruth, the defendant manufactured mining machinery and was sued
for contributory infringement for selling several patented machines.
67
Defendant's sales included sales of machines and replacement parts to the
Colorado School of Mines. 68 The School of Mines used its machines for
experimental purposes in the school's laboratory.' 69 The court held that most of
the defendant's sales constituted infringement, but that the sale of parts to the
School of Mines did not constitute infringement.70 The court reasoned that the
161. 3 WILLIAM C. ROBINSON, THE LAW OF PATENTS FOR USEFUL INVENTION § 898 (1890).
162. Id.
163. See Irving N. Feit, Biotechnology Research and the Experimental Use Exception to Patent
Infringement, 71 J. PAT. & TRADEMARK OFF. Soc'y 819, 827 (1989) (discussing criticism by two
commentators, Richard E. Bee and Ronald D. Hantman).
164. See Bruzzone, supra note 148, at 56 n.27 (noting that recent cases have cited Robinson's
explanations with approval).
165. For an excellent discussion of all the cases from 1813 to 1984 that are said to involve the
experimental use defense to patent infringement see Hantman, supra note 147, at 624-38.
166. 13 F. Supp. 697 (D. Colo. 1935). Analyzing the existing case law, Hantman found that only seven
cases (three involving private parties and four involving the United States Government) allowed the
experimental use defense. Hantman, supra note 147, at 624-38.
167. 13 F. Supp. at 699.
168. Id. at 699-700.
169. Id. at 703.
170. Id. at 713.
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"making or using of a patented invention merely for experimental purposes,
without any intent to derive profits or practical advantage therefrom, is not
infringement.' 7' Therefore, in Ruth, the District Court of Colorado seemed to
endorse the proposition that university research on patented technology in
furtherance of educational purposes does indeed fall within the purview of the
experimental use defense.
A more recent case out of the Court of Claims rejected the experimental use
defense and held the defendant liable for patent infringement damages . In
Pitcairn v. United States, the defendant manufactured several models of
helicopters that infringed eleven patents held by the plaintiff.'73 The defendant
argued that the use of helicopters for testing and experimental purposes should
not contribute to the plaintiffs infringement damages.' The appellate court
adopted the trial judge's opinion, which held that the experimental use defense
does not relieve the defendant of any liability.75 The trial judge reasoned that
"[o]bviously every new helicopter must be tested for lifting ability, for the effect
of vibration on installed equipment. .. and numerous other factors.' 76 The trial
judge further concluded that "[t]ests, demonstrations, and experiments of such
nature are intended uses of the infringing aircraft... and are in keeping with the
,0177
legitimate business of the using agency.
In 1984, the Federal Circuit heard one of the most important cases involving
the experimental use defense.7 1 In Roche Products, Inc. v. Bolar Pharmaceutical
Co., the defendant sought to market a generic version of the plaintiffs drug, a
sleeping pill, immediately upon the expiration of the plaintiffs patent term.' 71 It
obtained the drug from a foreign source and began testing the drug during the
final months of the plaintiffs patent term, in order to acquire FDA drug
approval. 8" The Federal Circuit relied on Pitcairn in rejecting the defendant's
experimental use argument and holding that the defendant infringed the
plaintiff s patent.'8 ' The court reasoned that the defendant's use of the patented
drug in hopes of marketing the drug was "solely for business reasons and not for
amusement, to satisfy idle curiosity, or for strictly philosophical inquiry.' 8 2 After
Roche, it was evident that the experimental use defense was a narrow defense and
171. Id.
172. Pitcairn v. United States, 547 F.2d 1106, 1126 (Ct. CI. 1977).
173. id. at 1110.
174. Id. at 1124-25.
175. Id. at 1126.
176. Id. at 1125.
177. Id. at 1125-26.
178. Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed. Cir. 1984). See Feit, supra note 163, at
830 (describing Roche as "[tihe most authoritative decision regarding the experimental use exception").
179. Roche, 733 F.2d at 860.
180. Id.
181. Id. at 863, 867.
182. id. at 863.
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could only be asserted by defendants to avoid liability for patent infringement in
limited instances. 183
That same year, Congress essentially overruled Roche by enacting 35
U.S.C.A. § 271(e), a narrow exception to patent infringement which allows
generic drug manufacturers to take steps to obtain FDA approval during the
patent term of the drug's patent owner.9" This statutory exception is available
only in factual situations similar to Roche, however, and does not broaden the
common law experimental use defense to patent infringement.
85
After Roche, the Federal Circuit left the experimental use defense untouched
until 2000. 86 In Embrex, Inc. v. Service Engineering Corp., the defendant hired
scientific consultants to run tests in an effort to design around the plaintiffs
patent, which was for a method of inoculating chicks against disease before
hatching.8 7 The court rejected the defendant's arguments that the tests were
merely experimental.' 88  The court, citing Roche, emphasized that the
experimental use defense is to be construed "very narrowly."'8 9 The court further
reasoned that the defense is limited to uses "for amusement, to satisfy idle
curiosity, or for strictly philosophical inquiry." '9° In a concurring opinion, Circuit
Judge Randall R. Rader argued that in light of a recent Supreme Court decision
involving an unrelated patent doctrine known as the doctrine of equivalents,' 9' the
experimental use defense should no longer exist at all.' 92 Based on the idea that
infringement does not depend on the intent of alleged infringer, Circuit Judge
Rader would refuse to recognize the defense "even in the extraordinarily narrow
form recognized in Roche."'1
93
Emerging from the case law, therefore, is an experimental use defense with
quite a narrow scope. Courts have agreed that uses for direct commercial
purposes or some foreseeable commercial benefit do not fall within the
defense.'9" The test that materialized was whether the use was for "amusement, to
183. See Hantman, supra note 147, at 620 (noting that most commentators agree that Roche has
"narrowed the experimental use exception, or at the very least, confirmed the narrowness of the exception").
184. See supra notes 143-45 and accompanying text (discussing the narrow statutory exception).
185. See supra notes 143-45 and accompanying text; but see Mueller, supra note 158, at 25-27
(describing the Hatch-Waxman Act, which is the legislation that added section 271(e), and arguing that "the
Hatch-Waxman Act supports... a broadened interpretation of the common law experimental use exemption
that does not turn solely on the commerciality of the accused infringer's use").
186. Embrex, Inc. v. Serv. Eng'g Corp., 216 F.3d 1343 (Fed. Cir. 2000).
187. Id. at 1346-47.
188. Id. at 1349.
189. Id.
190. Id.
191. See Warner-Jekinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 35 (1997) (holding that the
doctrine of equivalents does not require proof of the intent of the alleged infringer).
192. Embrex, 216 F.3d at 1353.
193. Id.
194. Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858, 863 (Fed. Cir. 1984).
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satisfy idle curiosity, or for strictly philosophical inquiry."'95 Notably, courts had
never found a defendant liable for patent infringement where the defendant's use
was entirely non-commercial and no commercial purpose was foreseeable.
C. Madey v. Duke University: Virtually Eliminating the Experimental Use
Defense
In 2002, the United States Court of Appeals for the Federal Circuit
eliminated the experimental use defense to patent infringement for virtually all
practical purposes.' 96 The Federal Circuit held that an alleged infringer cannot
assert the defense even if he is not "engaged in an endeavor for commercial
gain."' 97 The experimental use defense is now strictly limited to instances in
which the alleged infringer infringed "solely for amusement, to satisfy idle
curiosity, or for strictly philosophical inquiry.' 98 In order to describe the
reasoning behind the Federal Circuit's decision, a discussion of the facts of
Madey v. Duke University is necessary.199
Dr. John Madey, a physics professor, developed an innovative free electron
laser research lab while he was at Stanford University. °° Madey obtained two
patents based on equipment used in the lab.2"' Subsequently, Madey accepted a
position at Duke University and brought his free electron laser research lab with
him. °2 After Madey resigned from Duke, Duke continued to use the patented lab
equipment for research purposes."' Madey subsequently sued Duke for patent
infringement of his two patents.204
The district court ruled in favor of Duke on its motion for summary judgment
based on the experimental use defense.25 The district court recognized the
defense as precluding liability for patent infringement "for uses that ... are,
'solely for research, academic or experimental purposes."' 26 The district court
reasoned that Duke, as a university dedicated to teaching and research, is not
engaged in commercial applications of patents and, therefore, could properly
assert the experimental use defense.07
195. Embrex, Inc. v. Serv. Eng'g Corp., 216 F.3d 1343, 1349 (Fed. Cir. 2000).
196. Madey v. Duke Univ., 307 F.3d 1351 (Fed. Cir. 2002).
197. Id. at 1362.
198. Id.
199. Id. at 1351-52.
200. Id. at 1352.
201. Id.
202. Madey v. Duke Univ., 307 F.3d 1351, 1352 (Fed. Cir. 2002).
203. Id. at 1352-53.
204. Id. at 1353.
205. Id. at 1355-56,
206. Id. at 1355 (quoting the district court's summary judgment opinion).
207. Id. at 1356-57.
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Madey appealed the district court's decision to the Court of Appeals for the
Federal Circuit.08 He asserted several arguments in support of his claim that the
district court ruled incorrectly." As a threshold argument, Madey claimed that
the experimental use defense no longer exists at all in light of a recent Supreme
Court decision."0 Madey, making the same argument that Circuit Judge Rader
made in his Embrex concurrence, 2' argued the experimental use defense requires
that the intent of the alleged infringer be determined, contrary to Warner-
Jenkinson.' 2 The court rejected this argument based on the majority in Embrex
and concluded that a narrow experimental use defense does still exist.
213
Next, Madey argued that the district court erroneously shifted to him the
burden of proving that Duke's infringing use was not experimental.2 4 The court
agreed with Madey on this point and reaffirmed the principle that the alleged
infringer has the burden of establishing that its use was experimental and should
thus preclude'liability for infringement. 2 5
Finally, and most importantly, Madey argued that the district court applied an
overly broad experimental use defense that was inconsistent with existing Federal
Circuit precedent.21 6 The court accepted Madey's claim and reemphasized that the
defense is a narrow defense, as enunciated in the Pitcairn, Roche, and Embrex
line of cases. 2"1 The Federal Circuit rejected the district court's reliance on Ruth
since it is a Colorado District Court case and is therefore not binding on the
Federal Circuit.2s Further, the court in Ruth allowed the experimental use defense
based merely on the defendant's lack of commerciality and non-profit status as
an educational institution.2'9 The Ruth court did not thoroughly analyze the
character, nature, and effect of the alleged experimental use as is now required by
the Federal Circuit.220
208. Madey v. Duke Univ., 307 F.3d 1351, 1352 (Fed. Cir. 2002).
209. Id. at 1360.
210. Id. The decision upon which Madey relied was Warner-Jenkinson Co. v. Hilton Davis Chem Co.,
520 U.S. 17 (1997), which addressed the doctrine of equivalents. Madey, 307 F.3d at 1360. The doctrine of
equivalents is a doctrine unrelated to the experimental use defense.
211. See supra notes 191-93 and accompanying text (discussing Rader's argument that the experimental
use defense should no longer exist at all).
212. Madey, 307 F.3d at 1360-61.
213. Id. at 1361.
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216. Id. at 1361-62. The court relied on three Federal Circuit cases: Pitcairn v. United States, 547 F.2d
1106 (Ct. Cl. 1977), Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed. Cir. 1984), and Embrex, Inc. v.
Serv. Eng'g Corp., 216 F.3d 1343 (Fed. Cir. 2000). See supra text accompanying notes 172-77 (discussing
Pitcairn); supra text accompanying notes 178-83 (discussing Roche); supra text accompanying notes 186-93
(discussing Embrex).
217. Madey v. Duke Univ., 307 F.3d 1351, 1361-62 (Fed. Cir. 2002).
218. Id. at 1362; see supra text accompanying notes 165-71 (discussing Ruth).
219. Madey, 307 F.3d at 1362.
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The court proceeded to define the scope of the experimental use defense and,
in particular, its application to major research universities.22' While pointing out
that the defense is never available if the use is in any way commercial, the court
analyzed the commerciality of Duke University.222 The court noted that research
projects "unmistakably further the institution's legitimate business objectives,
including educating and enlightening [participating] students and faculty" as well
as "increase the status of the institution and lure lucrative research grants,
students and faculty. 223 In a footnote, the court suggested that Duke has an
aggressive patent licensing program that generates a significant amount of
224income for the university. The court went on to define the scope of theexperimental use defense as follows:
[R]egardless of whether a.particular institution or entity is engaged in an
endeavor for commercial gain, so long as the act is in furtherance of the
alleged infringer's legitimate business and is not solely for amusement,
to satisfy idle curiosity, or for strictly philosophical inquiry, the act does
not qualify for the very narrow and strictly limited experimental use
defense. Moreover, the profit or non-profit status of the user is not
determinative.225
Ultimately, the court concluded that the district court gave too much
consideration to Duke's educational status and failed to consider its legitimate
business objective.226 The court remanded the case and ordered the district court
to apply the experimental use defense test described above.227
In sum, the Madey court reaffirmed the very narrow experimental use
defense.28 The court held that the defense is strictly limited to instances where
the alleged infringer's use was "solely for amusement, to satisfy idle curiosity, or
for strictly philosophical inquiry. 2 29 However, the court went beyond this
traditional narrow formulation of the defense.230 It virtually eliminated the
experimental use defense for all practical purposes by holding that an alleged
infringer cannot assert the defense even if he is not "engaged in an endeavor for
commercial gain., 23' As one commentator pointed out, "the Court shifted the
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commercial nature of the experimentation and the profit versus non-profit status
of the alleged infringer to merely a question of whether the use was in
furtherance of the alleged infringer's legitimate business., 232 Therefore, under the
court's holding, universities can no longer assert the experimental use defense to
avoid patent infringement liability for research projects conducted exclusively for
educational purposes with arguably no commercial application whatsoever.233
Many universities and non-profit organizations hoped that the United States
Supreme Court would choose to hear the case and ultimately overturn the Federal
Circuit's decision in Madey.234 In addition, some commentators opposed to the
Madey decision hoped for the same.235 However, these hopes were crushed when
the Supreme Court denied Duke's petition for writ of certiorari.236
Commentary on Madey, for the most part, has been critical of the Federal
Circuit's decision to severely restrict the experimental use defense.237 It has been
argued that universities should be allowed to conduct experiments on patented
inventions and teach how patented inventions work. 3 8 The benefits that derive
from allowing a university to experiment on and teach certain patented
inventions include at least the following benefits: it is an efficient method of
distributing information to others; the process may reveal additional information;
the process may inspire further innovation; and, universities typically have ample
resources and support to conduct experiments.23 9 So, if the experimental use
defense is too narrow after Madey, how broad should the defense be? The proper
240scope of the experimental use defense has been discussed in the literature. Two
schools of thought have emerged. 24' First, some commentators assert that the• 242
experimental use defense should only apply when the use is noncommercial .
Second, some commentators assert that whether the defense can be raised should
• 243
depend on the nature of the experimentation at issue. If the alleged infringer is
232. Jennifer Miller, Sealing the Coffin on the Experimental Use Exception, 2003 DUKE L. & TECH.
REV. 12, 17 (2003).
233. Madey, 307 F.3d at 1361-63.
234. See Miller, supra note 232, at 20, 22 (stating that institutions which sought Supreme Court review
included the Association of American Medical Colleges, the Association of American Universities, Consumer
Project on Technology, and Public Knowledge).
235. See, e.g., id. at 22-23 (arguing that the Supreme Court should decide Madey since the Federal
Circuit ignored the history of the experimental use defense as applied to non-profit researchers).
236. Duke Univ. v. Madey, 123 S. Ct. 2639 (2003).
237. See, e.g., Saunders, supra note 152, at 262 (arguing that the court in Madey erred and "should have
instead crafted a more nuanced experimental use exception that protects educational experimentation on
patented inventions").
238. Id. at 265-66.
239. Id.
240. See id. at 266 (noting that scholars disagree on the proper scope of the experimental use defense).
241. Id. at 266-68.
242. Id. at 266-67.
243. Id. at 266-68.
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experimenting on an invention, then the experimental use defense should apply.44
If the alleged infringer is experimenting with an invention, however, then the
experimental use defense should not apply.45 Regardless of the precise scope of
the defense, commentators almost unanimously agree that it should be broader
than the Madey court's extremely narrow formulation.
In conclusion, it seems clear that Madey has severely restricted the ability of
non-profit research institutions such as universities to conduct research and
experiments. These institutions will likely be overly cautious, or even hesitant,
when conducting research involving cutting-edge technology that has been
patented. In order to use patented technology, research institutions will be forced
to enter licensing agreements with patent holders and may be prevented from
experimentation completely if a patent holder refuses to license a particular
invention.2 6 With the recent emergence of nanotechnology, considerable funding
has been dedicated to nanotechnology research and development. 47 Madey could




Biotechnology refers to the commercial development of scientific processes
that are primarily related to living organisms.4 9 In 1973, biotechnology became
generally accepted when professors Stanley N. Cohen and Herbert W. Boyer
found that a gene from one organism could confer its unique characteristics to a
host organism through in vitro recombinant DNA techniques. 50 Initially,
biotechnology inventions were not patentable subject matter. However, by the
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248. See Miller, supra note 232, at 20 (stating that "[Madey] threatens to stifle [scientific] research and
thereby endanger this nation's continued leadership in science and technology") (quoting Brief of Amici Curiae,
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McGeorge Law Review / Vol. 37
Chemistry is the branch of science that is most similar to biotechnology.252
Patents in the chemical arts, on the one hand, typically involve intermediate and
final products, processes of making those products, and methods of using final
chemical products. 253 Biotechnology patents, on the other hand, often cover basic
laboratory methods and materials (i.e., research tools) used to create
biotechnological products and processes.2' Biotechnological research tools have
been defined as "those patented tools used in development of new
biotechnological or pharmaceutical products that do not themselves physically
incorporate the tool. ' '255 Since biotechnology patents often involve research tools,
and not final products and processes like in the chemical arts, the experimental
use defense to patent infringement is particularly important in the context of
biotechnology. 56
Beginning in the late-1980s, several commentators have argued for a broader
experimental use defense in order to prevent, or at least mitigate, the stifling of
biotechnology innovation. Professor Rebecca S. Eisenberg initiated these
arguments in her seminal article Proprietary Rights and the Norms of Science in
Biotechnology Research.257  Eisenberg examined the interaction between
intellectual property law in the context of biotechnology inventions and
traditional norms governing scientific research.258 She concluded that the existing
patent system, with its broad right to exclude others, impairs free use of
259technology and the extension of new discoveries.
Eisenberg discussed the experimental use defense and suggested that its
narrow scope might impede the progress of science.26 She explained the situation
in which an infringer should be permitted to invoke the defense:
The case for allowing the defense appears strongest where the
subsequent user is attempting to devise alternatives to the patented
invention. In such a case, the interests of the research user are congruent
with the interests of the public and the scientific community in advancing
the state of human knowledge. The patent holder, by contrast, has an
interest in prolonging the period in which the public is dependent on the
patented technology. If the patentee sees the research user as a
competitor rather than a customer, she may refuse to license the
252. Feit, supra note 163, at 819.
253. Id.
254. Id.
255. Mueller, supra note 158, at 14.
256. See Feit, supra note 163, at 819 (stating that "basic laboratory methods and materials often
constitute the subject matter of [biotechnology] patent claims").
257. Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in Biotechnology Research, 97
YALE L.J. 177 (1987).
258. Id. at 177.
259. Id. at 177, 180.
260. See id. at 224-26 (discussing the experimental use defense).
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invention. Without an experimental use defense, it is possible that no one
would be able to build on the inventor's discovery until the patent
expired.26'
Eisenberg, however, acknowledged that too broad a defense could be
undesirable as well.262 Unduly restricting the patentee's rights would likely result
in a decreased incentive to innovate and less financial investment in research and
development. Ultimately, Eisenberg concluded that given the abundant
commercialization of biotechnology research discoveries, 263 "the experimental
use doctrine offers a potential mechanism for reconciling the patent monopoly
with the interest of the research community in building upon prior discoveries
through subsequent research." 2'6
Subsequently, Irving N. Feit argued for a broader experimental use defense
by way of legislative amendment in his article Biotechnology Research and the
Experimental Use Exception to Patent Infringement.26' Feit pointed out that many
pioneering developments in the biotechnology field have been patented and
threaten to disrupt further development. 266 He cautioned that threatening
universities, non-profit organizations, and commercial biotechnology companies
with patent infringement is undesirable and would lead to fewer resources
available for innovation.267 In light of case law suggesting that patentees have
exclusive rights to certain recombinant DNA techniques, Feit explained that
biotechnology firms are faced with a difficult decision. 268 "They can proceed with
the research despite a one-time, unrepeated, yet possibly willful infringement at
the very beginning of the project, or abandon the technology because a license
from a competitor is unavailable., 269 As a result, Feit proposed that an
experimental use defense should be created which permits the "making and using
of patented technology for the purpose of significantly improving it.
270
More recently, Professor Janice M. Mueller argued for a broadened rule
allowing "development use" of certain patented biomedical research tools in her
article No "Dillettante Affair": Rethinking the Experimental Use Exception to
261. Id. at 224-25. But see Jordan P. Karp, Note, Experimental Use as Patent Infringement: The
Impropriety of a Broad Exception, 100 YALE L.J. 2169, 2170 (1991) (arguing that the experimental use defense
should be applied "in a very restrictive manner, consistent with the purpose and function of the patent system").
262. Eisenberg, supra note 257, at 224.
263. Id. at 229.
264. Id. at 230. See also Ned A. Israelsen, 16 AIPLA Q.J. 457, 478 (1989) (stating that "infringement
should not be found unless the patented invention was practiced primarily to secure the benefits of that
invention [and] patent law should not confer on a patentee the right to keep others from improving on his
work").
265. Feit, supra note 163.
266. Id. at 820-21.
267. Id. at 822.
268. Id. at 838-39.
269. Id. at 839.
270. Id. at 840.
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Patent Infringement for Biomedical Research Tools."7' Mueller's analysis focused
exclusively on patented research tools used in the biotechnological and
biomedical industries. 72 She noted that when one seeks to acquire patented
research tools by way of a license, a significant possibility exists that
negotiations will fail and research will be delayed or forgone.273 Since research
tools are necessary to create further biotechnological innovation, Mueller
proposed that the experimental use defense be expanded to include a specific
"development use exception" for research tools. 24 Under this proposal, patented
research tools that are not available for licensing or purchase could be used in
creating biotechnology and biomedical inventions.2 75 However, in exchange for
reducing the patentee's exclusive rights, the user of the patented research tools
would be required to give the patentee a royalty payment based on the
276commercial value of the subsequently created invention.
Finally, one commentator has argued that the experimental use defense
should apply to public sector researchers in the context of biotechnology research
tools. 27 7 "[This] exception would cover noncommercial use of any biological
material, reagent, or research tool for which an equivalent substitute is not readily
available., 27' Absent this exception, a patentee would unjustifiably be able to
prevent not only patent-protected competition, but also competition resulting
from improving on the invention.279 As a result, a broadened experimental use
defense for public sector researchers is necessary to promote technological
progress while maintaining the patentee's incentive to innovate.' °
B. Nanotechnology Arguments
The arguments made to broaden the experimental defense in the context of
biotechnology apply equally in the context of nanotechnology. Today,
nanotechnology is at a similar point in its development as biotechnology was in
the 1970s. Just as biotechnology innovation developed dramatically throughout
the 1980s and 1990s, nanotechnology will likely see a similar expansion in the
next decade or two. In order to balance patentees' exclusive rights in
nanotechnology inventions with the overall promotion of nanotechnology
271. Mueller, supra note 158.
272. Id. at 9.
273. Id. at 15.
274. See id. at 54-66 (discussing a proposed "development use" model).
275. Id. at 54-55.
276. Id.
277. See Hoffman, supra note 251, at 1036-39 (discussing broadening the experimental use defense to
include public sector researchers as part of a three-pronged approach to alleviate problems associated with
patent stacking).
278. Id. at 1037.
279. Id.
280. Id. at 1038.
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innovation, a broader experimental use defense to patent infringement is
essential. Madey's proclamation that non-commercial experimental activity can
constitute patent infringement will unduly restrict nanotechnology innovation in
the years to come.
Biotechnology, it could be argued, is a unique scientific discipline in that
biotechnological innovation is highly dependent on access to fundamental
research tools. In fact, most of the arguments for a broader experimental use
defense in the biotechnology industry were made with respect to biotechnology
research tools. These research tools are essential to the furtherance of
biotechnological innovation since experimentation would not be possible without
access to these tools.
Nanotechnology, however, seems to parallel biotechnology in this respect.
Nanotechnology does indeed have certain pioneering technologies that are
essential to the creation of further developments and inventions. For example,
techniques such as scanning probe microscopy are essential for manipulating
atoms and arranging them in particular molecular configurations. In addition,
carbon nanotubes provide the building blocks for creating materials with superior
characteristics. If scanning probe microscopy, carbon nanotubes, or similar
fundamental tools are unavailable to research and development entities through
purchase or license from patent owners, the scientific progress of nanotechnology
will be stifled.
As with any emerging technology, a significant portion of nanotechnology
research and development is based in universities and non-profit organizations.
These research institutions and organizations may be hesitant to develop
nanotechnology for fear of patent infringement liability. In order to maintain the
United States' position as the global leader in nanotechnology, either the courts
or Congress must address the realistic potential that a nearly non-existent
common law experimental use defense will stifle nanotechnology innovation. A
reasonable solution, which would preserve patent owners' exclusive rights and
incentives to innovate, would be to permit non-commercial experimental use of
patented nanotechnology inventions.
V. CONCLUSION
Nanotechnology is at the forefront of the next technological revolution. With
federal funding for nanotechnology research and development in the billions of
dollars, nanotechnology will likely expand significantly in the next ten to twenty
years. In light of the Federal Circuit's decision in Madey v. Duke University, the
current narrow scope of the experimental use defense to patent infringement will
likely stifle nanotechnology innovation. The courts or Congress should listen to
the arguments that were made in the biotechnology arena and broaden the scope
of the experimental use defense to permit non-commercial experimental use.
